4//SEC Filing
CoLucid Pharmaceuticals, Inc. 4
Accession 0000911916-17-000086
CIK 0001348649operating
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 3:34 PM ET
Size
20.9 KB
Accession
0000911916-17-000086
Insider Transaction Report
Form 4
PAPPAS ARTHUR M
Director10% Owner
Transactions
- Disposition from Tender
Common Stock
2017-03-01$46.50/sh−5,528$257,052→ 0 total(indirect: By LLC) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−116,317$5,408,741→ 0 total(indirect: By PV III CEO Fund, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$36.50/sh−5,954$217,321→ 0 totalExercise: $10.00Exp: 2025-05-05→ Common Stock (5,954 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−1,871,049$87,003,779→ 0 total(indirect: By A. M. Pappas Life Science Ventures III, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$40.26/sh−8,897$358,193→ 0 totalExercise: $6.24Exp: 2026-05-10→ Common Stock (8,897 underlying)
Transactions
- Disposition from Tender
Common Stock
2017-03-01$46.50/sh−5,528$257,052→ 0 total(indirect: By LLC) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$40.26/sh−8,897$358,193→ 0 totalExercise: $6.24Exp: 2026-05-10→ Common Stock (8,897 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$36.50/sh−5,954$217,321→ 0 totalExercise: $10.00Exp: 2025-05-05→ Common Stock (5,954 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−1,871,049$87,003,779→ 0 total(indirect: By A. M. Pappas Life Science Ventures III, L.P.) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−116,317$5,408,741→ 0 total(indirect: By PV III CEO Fund, L.P.)
PV III CEO Fund, L.P.
10% Owner
Transactions
- Disposition from Tender
Common Stock
2017-03-01$46.50/sh−5,528$257,052→ 0 total(indirect: By LLC) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$40.26/sh−8,897$358,193→ 0 totalExercise: $6.24Exp: 2026-05-10→ Common Stock (8,897 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−116,317$5,408,741→ 0 total(indirect: By PV III CEO Fund, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$36.50/sh−5,954$217,321→ 0 totalExercise: $10.00Exp: 2025-05-05→ Common Stock (5,954 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−1,871,049$87,003,779→ 0 total(indirect: By A. M. Pappas Life Science Ventures III, L.P.)
A.M. Pappas & Associates, LLC
10% Owner
Transactions
- Disposition from Tender
Common Stock
2017-03-01$46.50/sh−116,317$5,408,741→ 0 total(indirect: By PV III CEO Fund, L.P.) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−5,528$257,052→ 0 total(indirect: By LLC) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$36.50/sh−5,954$217,321→ 0 totalExercise: $10.00Exp: 2025-05-05→ Common Stock (5,954 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$40.26/sh−8,897$358,193→ 0 totalExercise: $6.24Exp: 2026-05-10→ Common Stock (8,897 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−1,871,049$87,003,779→ 0 total(indirect: By A. M. Pappas Life Science Ventures III, L.P.)
Footnotes (6)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
- [F2]Represents securities held directly by A.M. Pappas Life Science Ventures III, L.P. AMP&A Management III, LLC is the general partner of A. M. Pappas Life Science Ventures III, L.P. and has a management agreement with Pappas Capital, LLC (fka A. M. Pappas & Associates, LLC) ("Pappas Capital"). As a result, Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned A.M. Pappas Life Science Ventures III, L.P. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F3]Represents securities held directly by PV III CEO Fund, L.P. AMP&A Management III, LLC is the general partner of PV III CEO Fund, L.P. and has a management agreement with Pappas Capital. As a result, Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned PV III CEO Fund, L.P. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F4]Represents securities held directly by Pappas Capital. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F5]Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
- [F6]Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Documents
Issuer
CoLucid Pharmaceuticals, Inc.
CIK 0001348649
Entity typeoperating
Related Parties
1- filerCIK 0001348649
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 3:34 PM ET
- Size
- 20.9 KB